Literature DB >> 24012682

Repeated resveratrol treatment attenuates methamphetamine-induced hyperactivity and [3H]dopamine overflow in rodents.

Dennis K Miller1, Clark E Oelrichs, Andrew S Sage, Grace Y Sun, Agnes Simonyi.   

Abstract

Resveratrol (3,4',5-trihydroxy-trans-stilbene) has been investigated for its potential as a prophylactic against degenerative diseases. It is a sirtulin activator that has recently been shown to regulate dopaminergic systems that contribute to the behavioral effects of methamphetamine and cocaine. The present study examined the impact of resveratrol on stimulant neuropsychopharmacology in rodents. Acute resveratrol treatment (20-40mg/kg) was ineffective to alter methamphetamine (0.5mg/kg)-induced hyperactivity in mice. Rodents received resveratrol once-daily for seven days to determine the effect of repeated polyphenolic treatment. Repeated resveratrol treatment (1-20mg/kg) decreased methamphetamine (0.5mg/kg)-induced hyperactivity in mice. Methamphetamine's (0.1-60μM) efficacy to evoke [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine was also attenuated by repeated resveratrol (1mg/kg) treatment. Repeated resveratrol treatment (10-20mg/kg) did not affect cocaine-induced hyperactivity in mice. Overall, these data suggest that resveratrol appears to have metaplastic and prophylactic activity to minimize the effects of methamphetamine to increase locomotor activity and evoke dopamine release. These data encourage future research to further investigate the relationship between polyphenolics and psychostimulant abuse and dependence.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cocaine; Dopamine; Locomotor; Methamphetamine; Sirtulin; Striatum

Mesh:

Substances:

Year:  2013        PMID: 24012682     DOI: 10.1016/j.neulet.2013.08.051

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  The role of reactive oxygen species in methamphetamine self-administration and dopamine release in the nucleus accumbens.

Authors:  Eun Young Jang; Chae Ha Yang; David M Hedges; Soo Phil Kim; Jun Yeon Lee; Tyler G Ekins; Brandon T Garcia; Hee Young Kim; Ashley C Nelson; Nam Jun Kim; Scott C Steffensen
Journal:  Addict Biol       Date:  2016-07-14       Impact factor: 4.280

2.  Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania.

Authors:  Samira Menegas; Camila L Ferreira; José Henrique Cararo; Fernanda F Gava; Gustavo C Dal-Pont; Maria L Gomes; Jotele F Agostini; Patrícia Fernanda Schuck; Giselli Scaini; Monica L Andersen; João Quevedo; Samira S Valvassori
Journal:  Metab Brain Dis       Date:  2019-03-27       Impact factor: 3.584

Review 3.  Role of natural products in mitigation of toxic effects of methamphetamine: A review of in vitro and in vivo studies.

Authors:  Mohammad Moshiri; Ali Roohbakhsh; Mahdi Talebi; Milad Iranshahy; Leila Etemad
Journal:  Avicenna J Phytomed       Date:  2020 Jul-Aug

4.  Resveratrol fails to affect cocaine conditioned place preference behavior, but alleviates anxiety-like behaviors in cocaine withdrawn rats.

Authors:  Panpan Hu; Wei Zhu; Chao Zhu; Lai Jin; Yun Guan; Xiaowei Guan
Journal:  Psychopharmacology (Berl)       Date:  2016-01-21       Impact factor: 4.530

5.  Sigma-1 receptor ligand PD144418 and sigma-2 receptor ligand YUN-252 attenuate the stimulant effects of methamphetamine in mice.

Authors:  Melissa A Tapia; John R Lever; Susan Z Lever; Matthew J Will; Eric S Park; Dennis K Miller
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

6.  Resveratrol modulates cocaine-induced inhibitory synaptic plasticity in VTA dopamine neurons by inhibiting phosphodiesterases (PDEs).

Authors:  Yan Li; Laikang Yu; Li Zhao; Fanxing Zeng; Qing-Song Liu
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

Review 7.  The Role of Chinese Herbal Therapy in Methamphetamine Abuse and its Induced Psychiatric Symptoms.

Authors:  Lin Chen; Qin Ru; Qi Xiong; Mei Zhou; Kai Yue; Yuxiang Wu
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.